Cervomed Inc (CRVO)

$7.68 +0.43 (5.93%)
Market Cap 71.06M
Revenue (ttm) 9.74M
Net Income (ttm) -16.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -167.25%
Debt to Equity Ratio 0.00
Volume 65,500
Avg Vol 93,574
Day's Range N/A - N/A
Shares Out 9.25M
Stochastic %K 90%
Beta -0.89
Analysts Strong Sell
Price Target $22.43

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
CEOBuysDisclosures
CEOBuysDisclosures Nov. 17 at 4:05 PM
$CRVO CEO purchased 7,847 shares at $7.53 for a total of $59,101. ALAM JOHN J now owns 1,474,978 shares. https://ceo-buys.com
0 · Reply
Messerschmittbf109
Messerschmittbf109 Nov. 17 at 2:33 PM
$CRVO smell odorous of take over ..15-18 $ Watch volumes
1 · Reply
BPler
BPler Nov. 17 at 2:11 PM
$CRVO
0 · Reply
BPler
BPler Nov. 17 at 2:08 PM
$CRVO Did we break just 9 again? 🎉🚀🎉
0 · Reply
5layer
5layer Nov. 17 at 1:40 PM
$CRVO let's go!
0 · Reply
BPler
BPler Nov. 16 at 9:37 PM
$CRVO Confidence at the Management, that adding with these prices are the best pre-christmas gift for them.
1 · Reply
5layer
5layer Nov. 14 at 10:12 PM
$CRVO wow this did ok today
1 · Reply
Messerschmittbf109
Messerschmittbf109 Nov. 14 at 9:39 PM
$CRVO only a take over could give us justice
1 · Reply
Messerschmittbf109
Messerschmittbf109 Nov. 14 at 8:38 PM
$UPST $CRVO I ’m laughing for last 15 minutes As usual 💩
0 · Reply
BPler
BPler Nov. 13 at 6:57 PM
$CRVO CFO also added for 26.000 USD https://de.investing.com/news/insider-trading-news/insiderkauf-bei-cervomed-cfo-elder-erwirbt-aktien-fur-26000-usdollar-93CH-3233493
1 · Reply
Latest News on CRVO
CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 4 weeks ago

CervoMed to Present at the Emerging Growth Conference

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 11:54 AM EDT - 5 weeks ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 8, 2025, 7:00 AM EDT - 5 weeks ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 2, 2025, 8:00 AM EDT - 6 weeks ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 17, 2025, 7:30 AM EDT - 2 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 2 months ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 11:20 AM EDT - 4 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 28, 2025, 7:00 AM EDT - 4 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

Jul 8, 2025, 7:00 AM EDT - 4 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 12, 2025, 8:00 AM EDT - 6 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar 31, 2025, 2:34 PM EDT - 8 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 25, 2025, 8:00 AM EDT - 8 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 22, 2025, 2:55 AM EDT - 8 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Mar 10, 2025, 4:05 PM EDT - 8 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Jan 29, 2025, 8:00 AM EST - 10 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 21, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the BIO CEO and Investor Conference

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 12, 2024, 8:00 AM EST - 1 year ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 7, 2024, 8:30 AM EST - 1 year ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

CervoMed to Participate in the Emerging Growth Conference 67

Feb 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 67

CervoMed to Participate in the Emerging Growth Conference 66

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

CervoMed Announces Completion of Merger with EIP Pharma

Aug 16, 2023, 1:58 PM EDT - 2 years ago

CervoMed Announces Completion of Merger with EIP Pharma

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

Aug 15, 2023, 4:01 PM EDT - 2 years ago

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

CEOBuysDisclosures
CEOBuysDisclosures Nov. 17 at 4:05 PM
$CRVO CEO purchased 7,847 shares at $7.53 for a total of $59,101. ALAM JOHN J now owns 1,474,978 shares. https://ceo-buys.com
0 · Reply
Messerschmittbf109
Messerschmittbf109 Nov. 17 at 2:33 PM
$CRVO smell odorous of take over ..15-18 $ Watch volumes
1 · Reply
BPler
BPler Nov. 17 at 2:11 PM
$CRVO
0 · Reply
BPler
BPler Nov. 17 at 2:08 PM
$CRVO Did we break just 9 again? 🎉🚀🎉
0 · Reply
5layer
5layer Nov. 17 at 1:40 PM
$CRVO let's go!
0 · Reply
BPler
BPler Nov. 16 at 9:37 PM
$CRVO Confidence at the Management, that adding with these prices are the best pre-christmas gift for them.
1 · Reply
5layer
5layer Nov. 14 at 10:12 PM
$CRVO wow this did ok today
1 · Reply
Messerschmittbf109
Messerschmittbf109 Nov. 14 at 9:39 PM
$CRVO only a take over could give us justice
1 · Reply
Messerschmittbf109
Messerschmittbf109 Nov. 14 at 8:38 PM
$UPST $CRVO I ’m laughing for last 15 minutes As usual 💩
0 · Reply
BPler
BPler Nov. 13 at 6:57 PM
$CRVO CFO also added for 26.000 USD https://de.investing.com/news/insider-trading-news/insiderkauf-bei-cervomed-cfo-elder-erwirbt-aktien-fur-26000-usdollar-93CH-3233493
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Nov. 13 at 3:55 PM
$CRVO CEO purchased 5,553 shares at $7.35 for a total of $40,815. ALAM JOHN J now owns 1,467,131 shares. https://ceo-buys.com
1 · Reply
5layer
5layer Nov. 13 at 3:52 PM
$CRVO under 10 is a steal
0 · Reply
5layer
5layer Nov. 13 at 2:46 PM
$CRVO
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Nov. 13 at 2:11 PM
$CRVO token open market buys by c suite. Much appreciated 👍
1 · Reply
Doki0926
Doki0926 Nov. 13 at 10:08 AM
$CRVO will it go up?
0 · Reply
BPler
BPler Nov. 12 at 9:03 PM
$CRVO https://www.marketbeat.com/instant-alerts/cervomed-inc-nasdaqcrvo-receives-consensus-rating-of-moderate-buy-from-brokerages-2025-11-12/
0 · Reply
5layer
5layer Nov. 12 at 2:02 PM
$CRVO
0 · Reply
BPler
BPler Nov. 12 at 7:02 AM
$CRVO https://beingpatient.com/dementia-with-lewy-bodies-pill-phase-3-clinical-trial/?utm_source=organic&utm_medium=social
1 · Reply
BPler
BPler Nov. 12 at 7:00 AM
$CRVO https://www.gurufocus.com/news/3201183/crvo-analyst-jason-kolbert-maintains-buy-rating-with-31-target-crvo-stock-news
0 · Reply
MV0527
MV0527 Nov. 12 at 1:56 AM
$CRVO
0 · Reply
5layer
5layer Nov. 11 at 5:04 PM
$CRVO
1 · Reply
Messerschmittbf109
Messerschmittbf109 Nov. 11 at 3:24 PM
$CRVO $JSPR boys .. but really are you thinking positive in this turd full of thi eves ?????
0 · Reply